Newborn hearing concurrent gene screening can improve care for hearing loss

A study on 14,913 Chinese newborns

Qiu Ju Wang, Ya Li Zhao, Shao Qi Rao, Yu Fen Guo, Yao He, Lan Lan, Wei Yan Yang, Qing Yin Zheng, Robert J. Ruben, Dong Yi Han, Yan Shen

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: Newborn hearing screening has been widely adopted and made an achievement to some degree. Current screening protocols rely solely on detecting existing auditory disorders at the time of screening and are unable to identify individuals susceptible to auditory disorders in later life. Even if the hearing loss newborn is referred, most cases could not be diagnosed until 6-12 months old with no etiology being elucidated. This study reports the first effort to combine traditional hearing screening with genetic screening to improve the efficacy of newborn hearing screening. Methods: This study was undertaken in 12 regional hospitals located in 11 provinces of China. 14,913 newborn babies received hearing concurrent genetic screening. The hearing screening was performed with OAE or AABR. Blood sample was collected with a universal newborn genetic screening card. And three common gene, mtDNA 12S rRNA, GJB2 and SLC26A4 were screened with standard protocol. Results: Among all the 14,913 newborns, 86.1% (12,837/14,913) individuals passed the first-step hearing screening, 7.8% (1168/14,913) babies passed only one side, and the other 6.1% (908/14,913) were bilaterally referred. Gene screening found 306 individuals had one or two mutant alleles, the carrier rate is 2.05% (306/14,913) among the entire newborn population. The risk for hearing loss was 100% (7/7) for those newborns carrying causative GJB2 or SLC26A4 mutations (homozygotes or compound heterozygotes), 14.4% (23/160) for GJB2 heterozygote carriers, 12.3% (15/122) for SLC26A2 heterozygous carriers, and the total prevalence of referral hearing screening was approximately 14.7% (45/306). However, 85.3% (261/306) newborns passed hearing screening among these carriers including 18 newborns with 12S rRNA mt.1555A> G pathogenic mutation, who would suffer from sudden hearing loss once applying aminoglycoside drugs. Conclusion: The cohort studies provided the essential population parameters for developing effective programs for hearing care of newborns in China. Hearing concurrent gene screening in newborns may confirm the abnormal results from hearing screening tests, help to find the etiologic of the hearing loss, and better recognize infants at risk for late-onset hearing loss occurring prior to speech and language development. In conclusion, a survey on 14,913 Chinese newborns proved that concurrent genetic screening could improve newborn hearing screening for hearing defects.

Original languageEnglish (US)
Pages (from-to)535-542
Number of pages8
JournalInternational Journal of Pediatric Otorhinolaryngology
Volume75
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Hearing Loss
Hearing
Newborn Infant
Genes
Genetic Testing
Heterozygote
China
Hearing Tests
Sudden Hearing Loss
Language Development
Mutation
Homozygote
Aminoglycosides
Mitochondrial DNA
Population
Cohort Studies
Referral and Consultation
Alleles

Keywords

  • Genetic screening
  • GJB2
  • MtDNA 12S rRNA
  • Newborn hearing screening
  • SLC26A4

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Pediatrics, Perinatology, and Child Health

Cite this

Newborn hearing concurrent gene screening can improve care for hearing loss : A study on 14,913 Chinese newborns. / Wang, Qiu Ju; Zhao, Ya Li; Rao, Shao Qi; Guo, Yu Fen; He, Yao; Lan, Lan; Yang, Wei Yan; Zheng, Qing Yin; Ruben, Robert J.; Han, Dong Yi; Shen, Yan.

In: International Journal of Pediatric Otorhinolaryngology, Vol. 75, No. 4, 04.2011, p. 535-542.

Research output: Contribution to journalArticle

Wang, Qiu Ju ; Zhao, Ya Li ; Rao, Shao Qi ; Guo, Yu Fen ; He, Yao ; Lan, Lan ; Yang, Wei Yan ; Zheng, Qing Yin ; Ruben, Robert J. ; Han, Dong Yi ; Shen, Yan. / Newborn hearing concurrent gene screening can improve care for hearing loss : A study on 14,913 Chinese newborns. In: International Journal of Pediatric Otorhinolaryngology. 2011 ; Vol. 75, No. 4. pp. 535-542.
@article{426b257050f9466c88b72c7efa25725a,
title = "Newborn hearing concurrent gene screening can improve care for hearing loss: A study on 14,913 Chinese newborns",
abstract = "Objective: Newborn hearing screening has been widely adopted and made an achievement to some degree. Current screening protocols rely solely on detecting existing auditory disorders at the time of screening and are unable to identify individuals susceptible to auditory disorders in later life. Even if the hearing loss newborn is referred, most cases could not be diagnosed until 6-12 months old with no etiology being elucidated. This study reports the first effort to combine traditional hearing screening with genetic screening to improve the efficacy of newborn hearing screening. Methods: This study was undertaken in 12 regional hospitals located in 11 provinces of China. 14,913 newborn babies received hearing concurrent genetic screening. The hearing screening was performed with OAE or AABR. Blood sample was collected with a universal newborn genetic screening card. And three common gene, mtDNA 12S rRNA, GJB2 and SLC26A4 were screened with standard protocol. Results: Among all the 14,913 newborns, 86.1{\%} (12,837/14,913) individuals passed the first-step hearing screening, 7.8{\%} (1168/14,913) babies passed only one side, and the other 6.1{\%} (908/14,913) were bilaterally referred. Gene screening found 306 individuals had one or two mutant alleles, the carrier rate is 2.05{\%} (306/14,913) among the entire newborn population. The risk for hearing loss was 100{\%} (7/7) for those newborns carrying causative GJB2 or SLC26A4 mutations (homozygotes or compound heterozygotes), 14.4{\%} (23/160) for GJB2 heterozygote carriers, 12.3{\%} (15/122) for SLC26A2 heterozygous carriers, and the total prevalence of referral hearing screening was approximately 14.7{\%} (45/306). However, 85.3{\%} (261/306) newborns passed hearing screening among these carriers including 18 newborns with 12S rRNA mt.1555A> G pathogenic mutation, who would suffer from sudden hearing loss once applying aminoglycoside drugs. Conclusion: The cohort studies provided the essential population parameters for developing effective programs for hearing care of newborns in China. Hearing concurrent gene screening in newborns may confirm the abnormal results from hearing screening tests, help to find the etiologic of the hearing loss, and better recognize infants at risk for late-onset hearing loss occurring prior to speech and language development. In conclusion, a survey on 14,913 Chinese newborns proved that concurrent genetic screening could improve newborn hearing screening for hearing defects.",
keywords = "Genetic screening, GJB2, MtDNA 12S rRNA, Newborn hearing screening, SLC26A4",
author = "Wang, {Qiu Ju} and Zhao, {Ya Li} and Rao, {Shao Qi} and Guo, {Yu Fen} and Yao He and Lan Lan and Yang, {Wei Yan} and Zheng, {Qing Yin} and Ruben, {Robert J.} and Han, {Dong Yi} and Yan Shen",
year = "2011",
month = "4",
doi = "10.1016/j.ijporl.2011.01.016",
language = "English (US)",
volume = "75",
pages = "535--542",
journal = "International Journal of Pediatric Otorhinolaryngology",
issn = "0165-5876",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Newborn hearing concurrent gene screening can improve care for hearing loss

T2 - A study on 14,913 Chinese newborns

AU - Wang, Qiu Ju

AU - Zhao, Ya Li

AU - Rao, Shao Qi

AU - Guo, Yu Fen

AU - He, Yao

AU - Lan, Lan

AU - Yang, Wei Yan

AU - Zheng, Qing Yin

AU - Ruben, Robert J.

AU - Han, Dong Yi

AU - Shen, Yan

PY - 2011/4

Y1 - 2011/4

N2 - Objective: Newborn hearing screening has been widely adopted and made an achievement to some degree. Current screening protocols rely solely on detecting existing auditory disorders at the time of screening and are unable to identify individuals susceptible to auditory disorders in later life. Even if the hearing loss newborn is referred, most cases could not be diagnosed until 6-12 months old with no etiology being elucidated. This study reports the first effort to combine traditional hearing screening with genetic screening to improve the efficacy of newborn hearing screening. Methods: This study was undertaken in 12 regional hospitals located in 11 provinces of China. 14,913 newborn babies received hearing concurrent genetic screening. The hearing screening was performed with OAE or AABR. Blood sample was collected with a universal newborn genetic screening card. And three common gene, mtDNA 12S rRNA, GJB2 and SLC26A4 were screened with standard protocol. Results: Among all the 14,913 newborns, 86.1% (12,837/14,913) individuals passed the first-step hearing screening, 7.8% (1168/14,913) babies passed only one side, and the other 6.1% (908/14,913) were bilaterally referred. Gene screening found 306 individuals had one or two mutant alleles, the carrier rate is 2.05% (306/14,913) among the entire newborn population. The risk for hearing loss was 100% (7/7) for those newborns carrying causative GJB2 or SLC26A4 mutations (homozygotes or compound heterozygotes), 14.4% (23/160) for GJB2 heterozygote carriers, 12.3% (15/122) for SLC26A2 heterozygous carriers, and the total prevalence of referral hearing screening was approximately 14.7% (45/306). However, 85.3% (261/306) newborns passed hearing screening among these carriers including 18 newborns with 12S rRNA mt.1555A> G pathogenic mutation, who would suffer from sudden hearing loss once applying aminoglycoside drugs. Conclusion: The cohort studies provided the essential population parameters for developing effective programs for hearing care of newborns in China. Hearing concurrent gene screening in newborns may confirm the abnormal results from hearing screening tests, help to find the etiologic of the hearing loss, and better recognize infants at risk for late-onset hearing loss occurring prior to speech and language development. In conclusion, a survey on 14,913 Chinese newborns proved that concurrent genetic screening could improve newborn hearing screening for hearing defects.

AB - Objective: Newborn hearing screening has been widely adopted and made an achievement to some degree. Current screening protocols rely solely on detecting existing auditory disorders at the time of screening and are unable to identify individuals susceptible to auditory disorders in later life. Even if the hearing loss newborn is referred, most cases could not be diagnosed until 6-12 months old with no etiology being elucidated. This study reports the first effort to combine traditional hearing screening with genetic screening to improve the efficacy of newborn hearing screening. Methods: This study was undertaken in 12 regional hospitals located in 11 provinces of China. 14,913 newborn babies received hearing concurrent genetic screening. The hearing screening was performed with OAE or AABR. Blood sample was collected with a universal newborn genetic screening card. And three common gene, mtDNA 12S rRNA, GJB2 and SLC26A4 were screened with standard protocol. Results: Among all the 14,913 newborns, 86.1% (12,837/14,913) individuals passed the first-step hearing screening, 7.8% (1168/14,913) babies passed only one side, and the other 6.1% (908/14,913) were bilaterally referred. Gene screening found 306 individuals had one or two mutant alleles, the carrier rate is 2.05% (306/14,913) among the entire newborn population. The risk for hearing loss was 100% (7/7) for those newborns carrying causative GJB2 or SLC26A4 mutations (homozygotes or compound heterozygotes), 14.4% (23/160) for GJB2 heterozygote carriers, 12.3% (15/122) for SLC26A2 heterozygous carriers, and the total prevalence of referral hearing screening was approximately 14.7% (45/306). However, 85.3% (261/306) newborns passed hearing screening among these carriers including 18 newborns with 12S rRNA mt.1555A> G pathogenic mutation, who would suffer from sudden hearing loss once applying aminoglycoside drugs. Conclusion: The cohort studies provided the essential population parameters for developing effective programs for hearing care of newborns in China. Hearing concurrent gene screening in newborns may confirm the abnormal results from hearing screening tests, help to find the etiologic of the hearing loss, and better recognize infants at risk for late-onset hearing loss occurring prior to speech and language development. In conclusion, a survey on 14,913 Chinese newborns proved that concurrent genetic screening could improve newborn hearing screening for hearing defects.

KW - Genetic screening

KW - GJB2

KW - MtDNA 12S rRNA

KW - Newborn hearing screening

KW - SLC26A4

UR - http://www.scopus.com/inward/record.url?scp=79952737401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952737401&partnerID=8YFLogxK

U2 - 10.1016/j.ijporl.2011.01.016

DO - 10.1016/j.ijporl.2011.01.016

M3 - Article

VL - 75

SP - 535

EP - 542

JO - International Journal of Pediatric Otorhinolaryngology

JF - International Journal of Pediatric Otorhinolaryngology

SN - 0165-5876

IS - 4

ER -